PriceTargets.com logo

Flexion Therapeutics - FLXN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.12 As of 11/19/2021 01:00 AM ET
+0 (0.00%)
Get New Flexion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FLXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FLXN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Flexion Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.12.

This chart shows the closing price for FLXN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Flexion Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2021Northland SecuritiesReiterated RatingOutperform ➝ Market PerformLow
10/19/2021HC WainwrightDowngradeBuy ➝ Neutral$25.00 ➝ $10.00Low
10/12/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
10/12/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$20.00 ➝ $12.00Medium
10/12/2021Raymond JamesDowngradeStrong-Buy ➝ Market PerformMedium
10/11/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$14.00 ➝ $10.00Medium
8/6/2021The Goldman Sachs GroupLower TargetNeutral$8.00 ➝ $6.00High
8/5/2021Needham & Company LLCLower TargetBuy$20.00 ➝ $18.00High
5/13/2021Credit Suisse GroupLower TargetOutperform$17.00 ➝ $14.00High
4/18/2021Royal Bank of CanadaReiterated RatingBuyHigh
4/14/2021Credit Suisse GroupLower TargetOutperform$18.00 ➝ $17.00High
4/14/2021Raymond JamesLower TargetStrong-Buy$18.00 ➝ $16.00High
4/14/2021HC WainwrightReiterated RatingBuyHigh
3/11/2021Credit Suisse GroupLower TargetOutperform$19.00 ➝ $18.00Low
1/27/2021Wells Fargo & CompanyLower TargetOverweight$16.00 ➝ $15.00Low
12/14/2020Needham & Company LLCReiterated RatingBuyHigh
11/30/2020HC WainwrightReiterated RatingBuyLow
11/5/2020Raymond JamesLower TargetStrong-Buy$19.00 ➝ $18.00High
11/5/2020BMO Capital MarketsLower TargetOutperform$23.00 ➝ $22.00High
8/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$15.00Low
8/6/2020HC WainwrightReiterated RatingBuy$25.00High
8/6/2020Northland SecuritiesInitiated CoverageBuy$35.00High
7/30/2020OppenheimerInitiated CoverageOutperform$19.00High
7/29/2020Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$19.00High
7/15/2020HC WainwrightReiterated RatingBuy$25.00High
6/25/2020HC WainwrightInitiated CoverageBuy$25.00High
6/2/2020Northland SecuritiesInitiated CoverageBuy$35.00Low
5/26/2020GuggenheimInitiated CoverageBuy$20.00High
5/8/2020Needham & Company LLCLower TargetBuy$30.00 ➝ $20.00High
5/8/2020Royal Bank of CanadaLower TargetOutperform$20.00 ➝ $18.00High
4/30/2020Needham & Company LLCLower TargetBuy$36.00 ➝ $30.00Medium
4/27/2020Northland SecuritiesInitiated CoverageBuy$35.00High
4/27/2020Raymond JamesLower TargetStrong-Buy$23.00 ➝ $20.00High
4/2/2020BenchmarkLower TargetBuy$25.00 ➝ $17.00Medium
4/1/2020Needham & Company LLCReiterated RatingBuy$36.00Medium
12/27/2019Needham & Company LLCReiterated RatingBuy$36.00Medium
12/27/2019BMO Capital MarketsReiterated RatingBuy$29.00Medium
12/27/2019BenchmarkBoost TargetBuy$19.00 ➝ $25.00High
12/27/2019Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $28.00High
12/5/2019Craig HallumInitiated CoverageBuy$24.00Low
11/25/2019BTIG ResearchInitiated CoverageBuy$27.00High
9/10/2019Northland SecuritiesSet TargetBuy$20.00High
5/9/2019Northland SecuritiesReiterated RatingBuy$20.00High
5/9/2019BenchmarkUpgradeHold ➝ Buy$19.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Flexion Therapeutics logo
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
Read More

Today's Range

Now: $9.12
Low: $9.12
High: $9.12

50 Day Range

MA: $9.20
Low: $9.12
High: $9.44

52 Week Range

Now: $9.12
Low: $4.30
High: $13.66

Volume

N/A

Average Volume

1,177,479 shs

Market Capitalization

$458.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Flexion Therapeutics?

The following equities research analysts have issued research reports on Flexion Therapeutics in the last year: StockNews.com.
View the latest analyst ratings for FLXN.

What is the current price target for Flexion Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Flexion Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Flexion Therapeutics in the next year.
View the latest price targets for FLXN.

What is the current consensus analyst rating for Flexion Therapeutics?

Flexion Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FLXN.

What other companies compete with Flexion Therapeutics?

Other companies that are similar to Flexion Therapeutics include Adlai Nortye, Fulcrum Therapeutics, IGM Biosciences, Acelyrin and Shattuck Labs. Learn More about companies similar to Flexion Therapeutics.

How do I contact Flexion Therapeutics' investor relations team?

Flexion Therapeutics' physical mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company's listed phone number is (781) 305-7777 and its investor relations email address is [email protected]. The official website for Flexion Therapeutics is www.flexiontherapeutics.com. Learn More about contacing Flexion Therapeutics investor relations.